Pharmacological action

Has antihypoxic effect. By directly affecting cardiomyocytes and neurons of the brain, the drug optimizes their metabolism and function. The cytoprotective effect is caused by an increase in the energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (enhancement of glycolysis and blockade of fatty acid oxidation).

Trimetazidine supports myocardial contractility, prevents a decrease in the intracellular content of ATP and phosphocreatinine. In conditions of acidosis normalizes the functioning of ion channels of membranes, prevents the accumulation of calcium and sodium ions in cardiomyocytes, normalizes the intracellular content of potassium ions.

Reduces intracellular acidosis and increased phosphate content, due to myocardial ischemia and reperfusion. Prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemic zone, prolongs the duration of the electrical potential, reduces the output of CKK from cells and the severity of ischemic myocardial damage.

Trimetazidine reduces the frequency of angina attacks, reduces the need for nitrate intake, after 2 weeks of use increases exercise tolerance, sharp fluctuations in blood pressure decrease. Reduces dizziness and noise in the ears of ischemic etiology. In vascular pathology, the eye restores the functional activity of the retina.

Indications

- IHD: prevention of angina attacks (in complex therapy);

- cochleovestibular disorders of ischemic nature, such as dizziness, tinnitus, hearing impairment;

- choreoretinal vascular disorders.